Search results
BEXIMCO currently has operations and investments across a wide range of industries including textiles, pharmaceuticals, PPE, ceramics, real estate development, construction, trading, marine food, information and communication technologies, media, financial services, and energy. [4] BEXIMCO's subsidiaries export products to 55 countries ...
The Dividend Payable/Unclaimed dividend as on September 30, 2022 includes Tk. 44,812K relating to year 2020-21 which has been paid but not yet claimed. The remaining balance relates to dividend for prior years unclaimed to date. For the Period For the Period July - September 2022 July - September 2021. 10.
Apr 27, 2022 · Beximco Limited has posted another stellar growth in sales and profits in the January-March quarter of fiscal 2021-22. Its total sales grew by 69% to reach Tk1,991 crore in the three months through March, against Tk1,179 crore over the same period a year ago, the company said in its quarterly financial statement. As sales revenue outgrew the ...
The address of Website is www.beximco.com STATEMENT OF FINANCIAL POSITIONS (UN-AUDITED) As at 31 December 2022 Taka ‘000 As at 31 December 2022 As at 30 Jun 2022 ASSETS Non - Current Assets 106,325,362 104,166,741 Property, Plant and Equipment 47,840,920 47,559,484 Investment Property 29,094,682 27,536,527
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. BPL is the largest exporter of generic drugs in the country and its state-of-the-art manufacturing facilities are already certified by major global regulatory authorities like TGA, GCC and ANVISA, while awaiting audits and approvals by US FDA ...
www.beximco.com
People also ask
What industries does Beximco invest in?
Who is Beximco Pharmaceuticals Limited?
Which subsidiaries have been consolidated with Beximco Pharmaceuticals Limited?
Where is Beximco based?
How will Beximco Pharmaceuticals contribute to Bangladesh's trillion-dollar journey?
What role did Beximco play in transforming the pharmaceutical industry?
Mar 12, 2023 · According to pharmaceutical intelligence firm Scrip, the industry’s top companies are forecasted to lose $200 billion between 2022 to 2030 due to the patent expiration of many drugs. This patent cliff opens up the market for the entry of generic medicine, with Bangladesh already positioned as an attractive hub backed by an established manufacturing base and skilled manpower.
